Article Text

Download PDFPDF
COVID-19 vaccine efficacy in a rapidly changing landscape
  1. Stephanie L Baer,
  2. Sarah Tran
  1. Department of Medicine, Augusta University, Augusta, Georgia, USA
  1. Correspondence to Dr Stephanie L Baer, Infection Control, Augusta VA Medical Center, Augusta, Georgia, USA; stephanie.baer{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The COVID-19 pandemic has presented new challenges to healthcare infrastructure, virology, vaccinology research, and implementation science. Misinformation concerning vaccines and non-pharmacologic measures to mitigate the spread of COVID-19 has made the study of vaccine efficacy extremely important for both transparency and accountability. The vaccines for COVID-19 were developed with urgency but without compromise of any safety or regulatory measures. They are undoubtedly the most efficacious means of disease mitigation we currently have available. As of this writing, 11.7 billion doses have been given worldwide, with 578 million in the USA alone.1

Unfortunately, due to the nature of the coronavirus, new variants continue to emerge. When dealing with a rapidly changing pathogen, it is essential to continuously review and update the known data, as manuscripts become outdated as soon as the first draft is written. In this issue of Journal of Investigative Medicine, Hirsh et al 2 …

View Full Text


  • Twitter @StephanieBaerMD

  • Contributors Both authors have reviewed and approved the content of the editorial.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Disclaimer The contents do not represent the views of the Department of Veterans Affairs or the US Government.

  • Competing interests SLB is a Journal of Investigative Medicine Editorial Board member. No other competing interests declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles